| Kiran Ubriani, MD | |
|
100 Retreat Ave, Suite 400, Hartford, CT 06106-2528 | |
| (860) 547-1278 | |
| (860) 547-1301 |
| Full Name | Kiran Ubriani |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 100 Retreat Ave, Hartford, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467409714 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Kiran Ubriani, MD 100 Retreat Ave, Suite 400, Hartford, CT 06106-2528 Ph: (860) 547-1278 | Kiran Ubriani, MD 100 Retreat Ave, Suite 400, Hartford, CT 06106-2528 Ph: (860) 547-1278 |
News Archive
Buruli ulcer - one of the most neglected among the NTDs - is a debilitating and stigmatizing disease. Affecting mainly children in West and Central Africa, the chronic disease results in devastating skin lesions and can lead to permanent disfigurement and long-term disabilities.
Researchers in the U.S. are suggesting that painkillers such as ibuprofen and naproxen can cut the risk of Parkinson's disease by as much as 60%.
Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal.
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.
› Verified 3 days ago
Gagandeep Singh, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-7446 Fax: 860-714-1508 | |
Yixia Ye, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 31 Seymour St Ste 205, Hartford, CT 06106 Phone: 860-524-2610 | |
Andrew P Scatola, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 85 Jefferson Street, Hartford Hospital Cardiology Dept, Hartford, CT 06106 Phone: 860-972-1212 | |
Dr. David Jay Altszuler, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 85 Seymour St Ste 719, Hartford, CT 06106 Phone: 860-522-0604 Fax: 860-522-0604 | |
Dr. Nisha Dhanabalsamy, MBBS Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-972-0549 | |
Sindhuja Palle, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour St, Hartford, CT 06106 Phone: 860-545-5000 | |
Dr. Jamie Matthew Roche, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-545-3359 |